Amgen (NASDAQ: AMGN) reported its Q4 results, with EPS coming in at $4.36, beating the consensus estimate of $4.12. Revenue grew 3% year-over-year to $6.85 billion, slightly missing the consensus estimate of $6.88 billion, driven by increased Other Revenue from the Eli Lilly and Company COVID-19 manufacturing collaboration.

Total product sales for Q4 decreased 1% year-over-year. Unit volumes increased 7% but were more than offset by lower net selling price and lower inventory levels.